ABSTRACT

Post-translational modifications (PTMs) regulate many aspects of protein function and are indispensable for the spatio-temporal regulation of cellular processes. The proteome-wide identification of PTM targets has made significant progress in recent years, as has the characterization of their writers, readers, modifiers and erasers. One of the most elusive PTMs is poly(ADP-ribosyl)ation (PARylation), a nucleic acid-like PTM involved in chromatin dynamics, genome stability maintenance, transcription, cell metabolism and development. In this article, we provide an overview on our current understanding of the writers of this modification and their targets, as well as the enzymes that degrade and thereby modify and erase poly(ADP-ribose) (PAR). Since many cellular functions of PARylation are exerted through dynamic interactions of PAR-binding proteins with PAR, we discuss the readers of this modification and provide a synthesis of recent findings, which suggest that multiple structurally highly diverse reader modules, ranging from completely folded PAR-binding domains to intrinsically disordered sequence stretches, evolved as PAR effectors to carry out specific cellular functions.

INTRODUCTION

Much of the complexity observed at the proteome level is due to post-translational modifications (PTMs) of proteins. PTMs can regulate all major aspects of protein function, including protein localization, interactions, protein stability and enzymatic activities. When considering proteins as the workhorses of a cell, PTMs could be seen as the equestrians that guide all efforts into the right direction. This direction might change over time, in particular when cells have to respond to internal and external cues, and most PTMs therefore do not constitute stable protein changes, but instead provide a means to dynamically regulate protein functions. This is due to the reversibility of most PTMs, and specific enzymes have evolved to antagonistically regulate PTMs by removing modifications from their target proteins. Thus, the interplay between the enzymes that covalently attach PTMs onto proteins, i.e. the writers, and the enzymes that revert these reactions, i.e. the erasers, determines the extent of protein modifications at any given point in time. Adding to this complexity, several PTMs can be modified themselves, and we are only beginning to understand how such modifications of PTMs contribute to the regulation of protein function. An important feature of many PTMs is that they can be recognized by specific protein domains, which thereby act as readers of PTMs, and the identification and characterization of such readers has become as pressing as the identification of PTM targets themselves. Moreover, in many cases reader proteins interact only transiently with their targets, and capturing these dynamics is important if we want to understand how PTMs and their binding partners regulate cellular functions.

Poly(ADP-ribosyl)ation (PARylation) is a PTM that has attracted considerable attention over the last decades due to its manifold cellular functions and the recently uncovered promises associated with its inhibition in cancer therapy. PARylation is defined by the successive conjugation of ADP-ribosyl units derived from NAD⁺ to generate polymeric ADP-ribose chains (1–3). Consequently, PARylation is significantly different from other typical PTMs in that it is neither a small moiety modification, such as phosphorylation, acetylation or methylation, nor does it represent a polypeptide PTM such as ubiquitylation or sumoylation. Rather, PARylation is characterized by the extensive conjugation of identical molecular building blocks, i.e. ADP-ribosyl units, which together form long and highly negatively charged linear or branched polymers. Despite these differences, PARylation shares many features with...
other PTMs: its formation relies on writers, i.e. enzymes capable of synthesizing ADP-ribose chains, and it is reversible, with modifiers and erasers working together to degrade poly(ADP-ribose) (PAR) chains (4). Moreover, several readers of PAR chains have been identified in recent years, and the structural diversity within this growing family of PAR-binding domains suggest that PAR can function as a versatile scaffold that dynamically regulates intracellular protein assembly.

In this article, we discuss recent developments that shed new light onto the multiple cellular functions of PAR and the enzymes involved in its generation and turnover. We then focus on PAR-binding modules, the readers of poly(ADP-ribose), and highlight how their structural and functional diversity makes them fit for purpose. Specifically, we discuss how the structural complexity of PAR itself is matched by the high degree of structural diversity found in its readers, ranging from completely folded PAR-binding domains to intrinsically disordered sequence stretches that make multivalent interactions with PAR and can phase separate to dynamically compartmentalize the intracellular space. As a unifying theme, we propose that the different modes of interaction are tightly linked to the functional consequences of PAR binding, and we discuss the implications for cellular PAR functions and their relevance for human disease.

Poly(ADP-ribosylation)

The first discovery of poly(ADP-ribosylation) was made by Chambon and colleagues more than 50 years ago (5). Interestingly, the polymer identified by Chambon and coworkers was initially assumed to resemble polyadenylic acid and was only later found to constitute a PTM rather than the product of an RNA polymerase. Nevertheless, the similarities between PAR and nucleic acids remain striking, and consequently the enzymes responsible for PAR formation were later called PAR polymerases (PARPs). PARP enzymes use nicotinamide adenine dinucleotide (NAD+) as their substrates, which they cleave into ADP-ribose and nicotinamide (NAM) (6). While the ADP-ribose moiety is covalently attached onto target proteins, NAM gets released. For PAR chains to be generated, additional NAD+ molecules have to be cleaved and the resulting ADP-ribose units have to be attached onto already existing ones. Thus, sequential reaction cycles are needed to transform mono-ADP-ribose into oligo(ADP-ribose) and eventually into poly(ADP-ribose) (7). The resulting polymer, which can be both linear and branched, is highly anionic due to two negative charges associated with each ADP-ribose moiety. The negative charge is one of the features shared between PAR chains and nucleic acids, which contain one (single-stranded RNA) or two (double-stranded DNA) negative charges per unit. PAR synthesis is tightly controlled in mammalian cells with steady-state levels being kept relatively low. Certain stimuli such as genotoxic stress or transcriptional activity can activate PARP enzymes, resulting in a rapid increase in PAR levels (7). PAR synthesis is transient, however, and PAR chains are efficiently removed by PAR degrading enzymes (8), exemplifying how the regulated interplay between writers and erasers dynamically controls the extent and duration of this PTM.

PAR polymerases and their cellular functions

At least eighteen proteins exist in human cells with a catalytic domain similar to the one present in PARP1, the first enzyme identified to synthesize PAR. However, not all of these proteins seem to be active or capable of generating PAR chains (8,9). Consequently, it has been proposed to rename the PARP protein family and refer to this class of proteins collectively as ADP-ribosyltransferases of the diphtheria toxin-like type (ARTDs) (Table 1) (10). Within this class, only four proteins have well documented PARylation activity: PARP1, PARP2 and the two tankyrases (8–10). The other family members include mono-ADP-ribosyltransferases as well as ARTD-like proteins without measurable enzymatic activity, and their emerging cellular functions have recently been covered elsewhere (7–11).

PAR synthesis can be observed under a variety of cellular conditions, most prominently under conditions of cell stress. Genotoxic stress in particular causes a rapid and pronounced increase in PAR levels, and PARylation has thus been studied mostly in the context of DNA damage signaling and repair (12). However, more recently also other functions of PARylation have emerged, including roles in DNA replication, transcription and RNA processing (13,14). Deregulated PAR homeostasis can thus impact cellular differentiation, embryonic development, inflammation, cellular metabolism, cancer development and aging (6–9). While PARP1 is responsible for most of the PAR synthesis observed in mammalian cells, PARP2 is also involved in several PAR-dependent functions and may have at least in part overlapping functions with PARP1, a notion that is supported by the embryonic lethality of mice lacking both enzymes and the elevated genomic instability observed in double-deficient embryonic fibroblasts (15). Thus, both PARP1 and PARP2 have important functions in the maintenance of genome integrity (16). Besides PARP1 and PARP2, also PARP3 plays important roles in the repair of DNA damage, although its capability to generate PAR has remained controversial (16–21).

The tankyrases, first identified as telomere-associated proteins (22), generate linear PAR chains of up to 20 ADP-ribosyl units (23). They function in spindle formation during mitosis (24), control centrosome function (25,26), regulate proteasome assembly and protein turnover to tune Wnt/β-catenin, PTEN-AKT and Hippo signaling, (27–31), and their regulation of protein stability has been implicated in the inflammatory bone destruction observed in Chéru-Bism (32,33).

While all writers of PAR generate the same anionic nucleic acid-like molecule, the cellular context in which the different PAR writers are activated can determine the extent of PARylation (chain length, branching complexity) and which proteins are targeted, providing a means for specific regulation of various cellular functions by PARylation.

Cellular targets of poly(ADP-ribosyl)ation

Due to the polydisperse and labile nature of PAR chains, its structural complexity and rapid turnover in cells, it has
Table 1. The PARP/ARTD protein family

| PARP     | ARTD   | Alternative names | PAR formation |
|----------|--------|-------------------|---------------|
| PARP1    | ARTD1  |                   | yes           |
| PARP2    | ARTD2  |                   | yes           |
| PARP3    | ARTD3  |                   | (?)           |
| PARP4    | ARTD4  | vPARP             |               |
| PARP5A   | ARTD5  | Tankyrase 1       | yes           |
| PARP5B   | ARTD6  | Tankyrase 2       | yes           |
| PARP6    | ARTD17 |                   |               |
| PARP7    | ARTD14 | tiPARP, RM1       |               |
| PARP8    | ARTD16 |                   |               |
| PARP9    | ARTD9  | BAL1              |               |
| PARP10   | ARTD10 |                   |               |
| PARP11   | ARTD11 |                   |               |
| PARP12   | ARTD12 | ZC3HDC1           |               |
| PARP13   | ARTD13 | ZC3HAV1, ZAP1     |               |
| PARP14   | ARTD8  | BAL2, CoaSt6      |               |
| PARP15   | ARTD7  | BAL3              |               |
| PARP16   | ARTD15 |                   |               |
| TPT1     | ARTD18 |                   |               |

Overview of the 18 PARP/ARTD family members, their alternative names and their confirmed activity as PAR polymerases.

been difficult to unambiguously identify cellular targets of this modification by mass spectrometry-based proteomics. However, in recent years significant technological progress has been made and various PAR enrichment strategies have been established to identify PAR-associated proteins and map PAR acceptor sites (34–45). This has led to the discovery that a plethora of nuclear proteins associates with PAR, including many DNA repair factors, chromatin remodelers, cell cycle regulators, RNA-binding proteins and transcription factors (42–45). Many of these proteins are likely to both interact non-covalently with PAR and to be targeted by covalent PARylation. The ever increasing number of PARylation targets is remarkable, as is the emerging diversity in PAR acceptor sites: lysine, arginine, glutamate, aspartate, cysteine, diphthamide, serine, threonine, phosphoserine and asparagine have all been identified as residues targeted by ADP-ribosylation, with the charged amino acids lysine, arginine, glutamate and aspartate being the ones most commonly targeted by covalent PARylation (9,40). This raises questions about the specificity of PAR attachment onto acceptor proteins and about the target amino acid preference. Given that the rate-limiting step for PAR formation is the enzymatic cleavage of NAD⁺ during the initiation reaction, one possibility could be that the subsequent attachment of ADP-ribose onto target proteins is favored by the availability of suitable amino acids on the exposed surface areas of proteins associated with or in the vicinity of activated PARP enzymes. In such a scenario, PARylation would comprise the context-dependent activation of the enzymes rather than from the site-specific modification of target proteins. In analogy to the SUMO concept (46), PAR might thus act as a molecular glue to enhance protein residence times and interactions. Of note, and consistent with such a model, PARP1 is the major acceptor of its own reaction product, and it could be that PARP1, but also other non-diffusible, chromatin-associated PAR acceptors such as the histones, primarily serve as a matrix for the PAR scaffold, which can then exert many of its functions by non-covalent interactions with PAR-binding proteins. Such a model is not mutually exclusive with specific functions of certain PAR acceptor sites, and further work is needed to dissect target site specificity and the functional consequences of site-specific PARylation.

Readers of poly(ADP-ribose) and their functions

The recent advancements in proteome-wide analyses of the cellular PARylome provide a hitherto unsurpassed opportunity to globally assess the relative contribution of PARP enzymes for PARylation in different cellular conditions and to identify their targets. This avenue will be particularly fruitful if combined with cellular assays to determine the functional role of PARylation sites in acceptor proteins. But already now, PAR proteomics has tremendously broadened our knowledge on PAR-associated proteins and thus provides a basis to better understand how PAR can exert its many biological functions. Hundreds of proteins interact directly or indirectly with PAR (42,43), and localized PAR formation can thus have profound effects on subcellular protein re-distribution and thereby influence many different signaling pathways, including the DNA damage response, transcriptional regulation, protein stability, cell fate decisions and cell death (47–50). Over the last years, several PAR-binding modules have been described (Figure 1), and their structural properties range from completely folded PAR-binding domains to disordered sequence stretches that can make multivalent interactions with PAR (Table 2). In light of this growing complexity, unifying models can carve out the essence of how proteins read the PAR signal and
Readers of poly(ADP-ribose). PAR polymerases use NAD\(^+\) to generate highly anionic linear and branched (not shown) PAR chains of different size and branching complexity. Besides the classical, well-characterized PAR reader modules WWE, PBZ, PBM, and macrodomains (top) also newly emerging PAR reader modules such as FHA, OB-fold, PIN domain, RRM, SR and KR repeats, RGG repeats and BRCT (bottom) appear as PAR readers and effectors. Multi-branched arrows indicate that the exact binding sites have not been defined.

how the different PAR readers evolved to appear designed to be fit for purpose.

The basic PAR-binding motif (PBM). The first reader module of PAR was described already 15 years ago as a loosely defined 20 amino acid cluster of hydrophobic amino acids spaced by basic residues (51). Following the original discovery of the PBM, a more recent in silico analysis revealed that more than 800 proteins contain this motif (42). Even a refined search using a more stringent motif based on experimentally derived interaction data still yielded over 500 predicted hits, suggesting that a sizable fraction of the proteome, including several DNA replication and repair proteins, cell cycle regulators, chromatin modifiers and RNA binding proteins, are able to directly interact with PAR (42). Structural data on the PBM and its interaction with PAR are not available and its affinity to PAR is likely due to electrostatic interactions between the positively charged amino acids present in the PBM consensus ([HKR]-X-X-[AIQVY]-[KR]-[KR]-[AILV]-[FIPV]) and the negatively charged PAR chains. Nevertheless, these interactions can reach relatively high affinities with \(K_D\) values in the sub-micromolar (\(10^{-7}\)) to nanomolar (\(10^{-9}\)) range (47), in particular when multiple PBMs within the same protein cooperate to bind long PAR chains. Given the large number of proteins containing the PBM consensus, the function of this PAR reading module might go well beyond the recruitment of just a few specific factors to sites of PAR formation, for instance at genomic lesions, and it could be that the collective or protein group assembly at PARylation sites fosters mutual interactions within multi-protein complexes that make specific reactions more efficient. Multivalent interactions with long chains of PAR may both increase affinity and specificity (52–55), and several nuclear proteins contain not just one but multiple PBMs (42,51), which may cooperate in their binding to PAR chains. Thus, the PBM seems to have evolved as a versatile PAR-reading module capable of dynamically interacting with PAR chains in a manner that takes polymer length and branching complexity into account to drive multi-protein assemblies at PARylation sites.

The PAR-binding zinc finger (PBZ). In 2008, a Cys\(_2\)-His\(_2\) type zinc finger motif with PAR-binding properties was identified in the two DNA damage responsive proteins APLF (aprataxin and PNK-like factor) and CHFR (checkpoint with forkhead and ring finger domains) (56). The structure of this relatively small motif of less than 30 amino acids with the consensus sequence [K/R]-X-X-C-X-[F/Y]-G-X-X-C-X-[K/R]-[K/R]-X-X-X-H-X-X-X-[F/Y]-X-H was solved two years later (57–60). The biochemical and structural evidence suggests that two consecutive ADP-ribose moieties within the PAR chain are bound by the PBZ (59,60). Interestingly, and in contrast to the single PBZ present in CHFR, APLF contains a tandem PBZ, and the two zinc finger
PBZ motif was recently identified in the checkpoint kinase DNA damage response and cell cycle regulation. In addition to proteins and specifically regulate their functions in the specialized PAR reader module, which is present in only very few proteins and has a modular organization that combines multiple PAR reader domains within the same polypeptide chain (e.g. RRM, PIN domains, OB-fold, RGG repeats). Currently known PAR reader modules are listed together with their structural features, interaction mode with PAR, and main functions associated with PAR-binding. Examples and key references are provided. Notably, several proteins contain multiple PAR-binding modules, i.e. have a modular organization that combines multiple PAR reader domains within the same polypeptide chain (e.g. RRM, PIN domains, OB-fold, RGG repeats).

### Table 2. Readers of poly(ADP-ribose)

| Reader Module | Module size | Defined protein fold | Interaction mode | Main functions | Examples | Key references |
|---------------|-------------|----------------------|------------------|----------------|----------|----------------|
| PBM           | =20 residues | yes                  | DNA replication and repair, cell cycle regulation, chromatin architecture, RNA metabolism | H1, H2A, H2B, H3, H4, p21, p53, XRCC1, XPA, MSH6, ERCC6, ATM, MRE11, DNA-PKcs, Ku70, WRN, DNA Ligase 3, Poly(ADP-ribose) polymerase, TERT, DEK, CAD, CENP-A, CENP-B, APLF, CHFR, PKR, ARID2 | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| PBZ           | =30 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| Macromodules  | =130–190 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| WVE           | =80–100 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| FHA/BRCT      | =80–100 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| RRM           | =60–80 residues | yes                  | DNA damage signaling and repair, RNA metabolism | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| SR repeats and KR-rich motifs | variable | no                   | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| OB-fold       | =70–150 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| PIN domains   | =130–150 residues | yes                  | DNA damage signaling and repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |
| RG/RGG repeats | variable | no                   | Stress granule assembly, liquid demixing, DNA repair | APLF, CHFR | Ahel et al. (2008), Rulten et al. (2014), Isabelle et al. (2015), Timinszky et al. (2009), Li et al. (2010) |

Motifs cooperate to achieve high affinity PAR binding (59,60). Besides APLF and CHFR, which are third human protein, SNM1A/DCLRE1A (DNA cross-link repair 1A protein), contains a PBZ (56). However, compared to APLF and CHFR, the PBZ of SNM1A/DCLRE1 lacks critical PAR-binding residues, suggesting that it may not bind to PAR (58). Thus, only two proteins in the human proteome seem to have acquired high affinity PAR-binding zinc fingers, and their cellular functions are closely linked to PAR induction: the recruitment of APLF to sites of DNA damage to promote repair by non-homologous end-joining (NHEJ) is critically dependent on PAR formation and on the tandem PBZ (20,61), while similarly the CHFR-dependent anaphase checkpoint is dependent on PAR synthesis and an intact PBZ (56,58). The PBZ thus represents a highly specialized PAR reader module, which is present in only very few proteins and specifically regulates their functions in the DNA damage response and cell cycle regulation. In addition to the canonical PBZ, a putative variation of the PBZ motif was recently identified in the checkpoint kinase CHK1, and shown to confer affinity to PAR (62). Potentially, other hitherto unknown variations of the PBZ might exist and their PAR-binding potential remains to be tested.

**Macromodules.** In contrast to PBM and PBZ, macromodules are sizable, globular reader modules containing between 130 and 190 amino acids. Macromodules bind to various molecules that comprise ADP-ribose as component, including O-acetyl-ADP-ribose, mono- and also poly(ADP-ribose) (63–65). It should be noted, however, that based on structural data macromodules interact also poly(ADP-ribose) (63–65). It should be noted, however, that based on structural data macromodules interact also poly(ADP-ribose) (63–65). It should be noted, however, that based on structural data macromodules interact.
containing ADP-ribose readers in vivo is still missing. Based on amino acid sequence comparison, 11 human proteins contain a macrodomain, including the PARP/ARTD family members PARP9, PARP14 and PARP15, the histone variants macroH2A1.1, macroH2A1.2 and macroH2A2, as well as macroD1/MDO1, macroD2/MDO2, C6orf130/TARG, ALC1/CHD1L and GDAP2. Interestingly, the macrodomain-containing PARP/ARTD family members contain two (PARP9, PARP15) or even three consecutive macrodomains (PARP14) (66). Not all macrodomains identified seem to be able to bind to PAR, but some of the ones that are able to recognize PAR have even acquired catalytic activity and participate in the degradation of PAR (8). Thus, relatively subtle sequence variations within the macrodomain fold can transform this module from a non-PAR-binder to a high affinity PAR reader, and even to an ADP-ribose eraser—a unique feature among the growing number of PAR readers (see below).

WWE domains. The WWE domain, named after its most conserved amino acids tryptophan (W) and glutamate (E), is found in 12 human proteins. Interestingly, these PAR readers are present in only two classes of proteins: PARP/ARTD family members themselves, and ubiquitin ligases (67). The presence of both WWE domains and macrodomains in several PARP/ARTD family members suggests an intriguing and largely unexplored interplay between writing and reading the PAR signal. In this regard, it is noteworthy that within the PARP/ARTD family a clear separation into PAR writers and readers seems to exist, because macro- and WWE domains are present only in family members that do not synthesize PAR, and they are absent from the PAR generating enzymes PARP1, PARP2, PARP5A and PARP5B. Unlike macrodomains, the WWE domains interact with iso-ADP-ribose, a structure comprising parts of two consecutive ADP-riboseyl units within the PAR chain (67). Consistent with a binding preference for iso-ADP-ribose, the experimentally derived $K_D$ values are relatively low for ADP-ribose (in the millimolar range), but reach sub-micromolar values (10^{-7}) for iso-ADP-ribose (47). Four residues of the WWE domain are crucial for the interaction with iso-ADP-ribose and these are conserved in PARP11, PARP13 and the first WWE of PARP12, but neither in the second WWE of PARP12, nor in PARP7, or PARP14 (67). Thus, similar to the macrodomains, not all WWE domains seem to possess PAR-binding potential. The four residues crucial for PAR binding are also present in the WWE domains of several ubiquitin E3 ligases, including RNF146/Iduna, HuWE1/Mule, TRIP12/ULF, and Deltex1, Deltex2 and Deltex4. In contrast to the poorly understood role of WWE-mediated PAR reading by members of the PARP/ARTD family, a clear functional link has been established between PAR binding and ubiquitin ligase activity. The best-studied example is the E3 ligase RNF146/Iduna, which catalyzes PAR-dependent ubiquitylation of target proteins to mediate their proteasomal degradation (67,68). In this case, PAR-recognition on target proteins by the WWE domain is a prerequisite for their ubiquitylation. PAR-dependent ubiquitylation is thus reminiscent of the SUMO-dependent ubiquitylation that is carried out by SUMO-targeted ubiquitin ligases (STUbLs) (69). Interestingly, PAR-dependent ubiquitylation is employed both by the cellular response to DNA damage, where PARP1 mediates the PARylation required for RNF146/Iduna targeting (68), and in Wnt/β-catenin signaling, where the tankyrase PARylate the protein axin to allow for its recognition by RNF146/Iduna (28,29). PAR-dependent ubiquitylation by RNF146/Iduna depends on the allosteric activation of its RING domain via a major intramolecular conformational rearrangement upon PAR-binding (70). Thus, reading the PAR signal can provide a switch that turns an inactive catalytic domain into an active one. The list of substrates for PAR-dependent ubiquitylation is growing, and it includes the regulator of Wnt/β-catenin signaling axin (28,29), adaptor protein 3BP2 (32,33), and the DNA repair factors Ku70, XRCC1, DNA ligase III, PARP1 and PARP2 (68). Whether the ubiquitin ligase activities of Deltex1, Deltex2 and Deltex4, involved in notch signaling, or of the HECT domain-containing ubiquitin E3 ligases HUWE1/Mule and TRIP12/ULF, both involved in genome integrity maintenance (71,72), are regulated by WWE domain-mediated PAR recognition remains to be investigated. Nevertheless, PAR-dependent ubiquitylation by PAR-targeted ubiquitin ligases (which, by analogy to STUbLs, could be dubbed PTUbLs) has emerged as one of the most exciting cellular functions of reading the PAR signal.

FHA and BRCT domains. FHA (Forkhead-associated) and BRCT (BRCA1 C-terminal) domains have been studied mainly as readers of phosphorylation marks and modulators of protein-protein interactions (73). Recently, however, it was shown that FHA and BRCT domains also confer affinity to PAR (74–76). Similar to phosphorylation, the PAR signal is negatively charged, which could mediate electrostatic interactions with the phosphor-binding pockets of FHA and BRCT domains. Interestingly, the FHA domains of APTX (Aprataxin) and PNKP (Polynucleotide kinase-3′-phosphatase) interact with iso-ADP-ribose, the structure also recognized by WWE domains, whereas the BRCT domains of DNA Ligase IV, XRCC1 and NBS1 recognize the ADP-ribosyl moiety within PAR (74,75). Also the BRCT domains of BARD1 (BRCA1-associated RING domain protein 1) have affinity for PAR and contribute to the recruitment of the BRCA1/BARD1 complex to DNA double-strand breaks (76). The wave of DNA damage-induced PARylation might thus serve as a molecular trap to catch proteins required during subsequent stages of repair, and cooperate with additional modifications, such as the phosphorylation of H2AX by DNA damage response (DDR) kinases and the ensuing chromatin ubiquitylation, to ensure their sustained retention on the damaged chromatin.

RNA and DNA binding motifs. One of the most intriguing recent discoveries is that PAR can be recognized by protein motifs that are known to bind to RNA or DNA. This development gives rise to the notion that important cellular functions of PAR could reside in its early recognized similarity to other nucleic acids and its potential to outcompete
the binding of RNA- and DNA-associated proteins to their target nucleic acids under conditions when PAR levels peak.

The RRM. The RNA recognition motif (RRM) is one of the most abundant RNA binding domains with a broad spectrum of target RNAs and capable of recognizing multiple RNA sequences and structures. It is therefore not too surprising that also PAR as a nucleic acid-like molecule lacking sequence information can be recognized by RRMs. In the cellular context, where not only affinities matter but also the dynamic changes in local concentrations of available molecules to interact with, even relatively unspecific interactions can dynamically alter macromolecular assemblies and can therefore be relevant for cell function. Several examples of RRM-containing proteins, which assemble at sites of PAR formation to promote genome stability, exist, including proteins of the heterogeneous nuclear ribonucleoprotein (hnRNP) family (77,78), the RNA processing factors NONO and RBMX (79,80), and a growing number of transcription factors (81). Since RNA and PAR can compete for the same binding proteins (79), peaks in PAR levels may dynamically outcompete RNA binding and assemble various RNA-binding proteins at PARylation sites, including sites of genomic lesions.

SR repeats and KR-rich motifs. Serine/Arginine repeats (SR repeats) are found in a second group of RNA-binding proteins, in particular in regulators of splicing, and several splicing factors were shown to interact with PAR, including ASF/SF2, SF3A1, SF3B1 and SF3B2 (43,82). The affinity for both RNA and PAR is likely to be mediated by the cluster of positive charges associated with the arginine-rich repeats, and electrostatic interaction with PAR therefore is a recurrent theme in reading the PAR signal. In line, PAR-binding was also observed for lysine- and arginine-rich (KR-rich) motifs present in the nucleosome remodeler dMi-2 (83).

The OB-fold. The oligonucleotide/oligosaccharide-binding fold (OB-fold) is a 70–150 amino acid containing five-stranded beta-barrel with a terminating alpha-helix found in proteins that bind to single-stranded nucleic acids or oligosaccharides. Recent evidence suggests that, similar to the RNA-binding motifs discussed above, also the OB-fold is a reader of PAR(84,85). The OB-fold recognizes the PAR-specific iso-ADP-ribose and this binding is required to bring the single-stranded DNA-binding protein SSBI to sites of DNA damage (84), as well as for the early recruitment of BRCA2 to DNA break sites (85). Just like RNA and PAR, single-stranded DNA is a flexible polymer with free rotation around the phosphodiester backbone that links adjacent nucleotides, and its binding to OB-folds relies at least in part on electrostatic interactions, allowing for a dynamic competition between single-stranded DNA and PAR for OB-fold interactions.

PIN domains. PIN domains, named after the amino-terminus of the PilT protein (PilT N-terminus), are evolutionarily conserved single-stranded DNA- and RNA-recognition domains with nucleolytic function, and represent the latest addition to the growing spectrum of PAR-binding domains (86). The PIN domains of EXO1, GEN1 and SMG5 recognize PAR with relatively high affinity (a dissociation constant of 200–300 nM was determined for the EXO1 PIN domain), and the PIN domain mediated interaction with PAR is required for the early recruitment of EXO1 to DNA break sites for efficient DNA end resection (86). Together with the recent finding that the DNA-binding domains of many transcription factors contribute to their PAR-dependent recruitment to DNA damage sites (81) these data suggest that DNA- and PAR-binding are in fact overlapping features of a considerable number of proteins.

RG/RGG motifs. The RG/RGG motifs, regions rich in arginines (R) and glycines (G), also termed glycine-arginine-rich (GAR) domains, are found in more than 1000 human proteins involved in numerous cellular functions, including DNA damage signaling, transcription and RNA processing (87). The accumulation of positive charges not only confers affinity to RNA, but has recently also been shown to mediate interactions with PAR. This was first suggested by a study showing that the rapid recruitment of the nuclease MRE11 to genomic lesions was dependent on its GAR domain as well as on the formation of PAR (88). Also the stress granule component G3BP1 binds PAR via its GAR domain, and the G3BP1-mediated stress granule assembly in response to genotoxic stress is impaired by PARP inhibition (43). More recently, RGG-rich regions in the RNA-binding proteins FUS/TLS, EWS/EWSR1, TAF15, SAFB1, SAF-A and hnRNPU1/2 were shown to be involved in the PAR-dependent assembly of these proteins at sites of DNA damage (81,89–94). Extended RGG repeats, as observed in several RNA-binding proteins, can be regarded as low complexity domains, and, similar to the PBM, their structural flexibility combined with their positive charge may allow them to make multivalent electrostatic interactions with polydisperse PAR chains leading to PAR-nucleated multi-protein assemblies.

PAR-seeded liquid demixing

Interestingly, in the case of FUS/TLS, EWS/EWSR1 and TAF15, the 18–22 RGG repeats within the carboxy-terminal half of the proteins are coupled to extended prion-like, aggregation-prone low complexity domains at the amino-termini of these proteins (95). The high degree of low complexity sequences allows these proteins to undergo intracellular phase transitions and thereby demix from the soluble environment (96,97). Such liquid demixing by phase separation can dynamically re-organize the soluble intracellular space by generating membrane-less compartments (98,99). Interestingly, the nucleic acid-like polymer PAR can function as a molecular seed for the dynamic liquid demixing of these proteins at sites of DNA damage (95,100). While genomic lesions could be a prime trigger for PAR-seeded liquid demixing, we envision that dynamic, PAR-seeded compartmentalization might be a more common theme in PAR biology. Indeed, PAR-seeded phase separations may occur not only in response to DNA damage, but in a variety of cellular contexts in which PAR has been reported to initiate protein assemblies into membrane-less compartments. These include the formation of stress gran-


Modifiers and erasers of poly(ADP-ribose)

The assembly of numerous cellular proteins at sites of PAR formation bears inherent risks. First, several PAR reader modules possess dual affinity for PAR and RNA/DNA, and—while cells may want to transiently assemble these proteins at sites of PARylation—it would be detrimental to stably sequester them away from their RNA or DNA targets. Second, while the PAR-seeded assembly of intrinsically disordered proteins with extended stretches of low complexity sequences can sub-divide the intracellular space through phase separation, it would be fatal if these delicate compartments turned into irreversible protein aggregates. Third, the generation of PAR is associated with the consumption of significant amounts of NAD$^+$ and has the potential to cause a cellular energy crisis by inhibiting glycolysis (108,109). For all these reasons, it is at least as important to terminate PAR signaling in a timely manner, as it is to trigger PAR formation in the first place. Several enzymes have been identified that can cleave PAR and remove ADP-ribose from modified proteins (8). The most important enzyme for the degradation of chromatin-associated PAR is poly(ADP-ribose) glycohydrolase (PARG). PARG exhibits both exo- and endo-glycohydrolase activity, with the latter being capable of generating protein-free PAR fragments, which can potentially serve as binding partners for various PAR readers (110,111). However, its predominant exo-glycohydrolase activity suggests that the primary mode how PARG degrades PAR is through sequential removal of ADP-ribose moieties from the distal end of the polymer (112). Interestingly, although unrelated in amino acid sequence, the PARG catalytic domain has structural homology to PAR-binding macrodomains (113), linking, from a structure-function perspective, of cleaving the protein-ADP-ribose bond. This group of macrodomain-containing erasers includes macrodomain-containing protein 1 (macroD1/MDO1), macrodomain-containing protein 2 (macroD2/MDO2) and terminal ADP-ribose glycohydrolase (TARG/C6orf130) (116–118). While macroD1/MDO1 and macroD2/MDO2 act specifically only on mono-ADP-ribosylated substrates (116,117), TARG/C6orf130 was reported to remove PAR chains en bloc from target proteins and thereby release free PAR, which may be further processed or serve as a scaffold for PAR-binding proteins (118). Interestingly, all three proteins show a preference for ADP-ribose attached to glutamic acid (116–118). This, together with the notion that ADP-ribose attachment may occur on both acidic and basic residues, suggests that writers and erasers might have evolved distinct substrate specificities, and that therefore different classes of enzymes might exist to counteract the reaction product of a single class of PAR polymerases. Room remains for putative enzymes to be discovered that can remove ADP-ribose from basic residues. In addition to PARG and the macrodomain-containing enzymes, ADP-ribosylhydrolase 3 (ARH3), a member of a structurally distinct class of ADP-ribosylhydrolases, can also degrade PAR (8). The major fraction of ARH3 is found in the cytoplasm, and consistent with its inability to cleave the last, protein-bound ADP-ribose, its physiological function could be the hydrolysis of free PAR chains released during apoptotic cell death (119). More recently, Nudix hydrolases (Nucleoside diphosphate-linked moiety X hydrolases) emerged as new targets of PARylation—thereby removing PAR and thereby releasing free PAR from target proteins and thereby release free PAR, which may be further processed or serve as a scaffold for PAR-binding proteins (118). Interestingly, all three proteins show a preference for ADP-ribose attached to glutamic acid (116–118). This, together with the notion that ADP-ribose attachment may occur on both acidic and basic residues, suggests that writers and erasers might have evolved distinct substrate specificities, and that therefore different classes of enzymes might exist to counteract the reaction product of a single class of PAR polymerases. Room remains for putative enzymes to be discovered that can remove ADP-ribose from basic residues. In addition to PARG and the macrodomain-containing enzymes, ADP-ribosylhydrolase 3 (ARH3), a member of a structurally distinct class of ADP-ribosylhydrolases, can also degrade PAR (8). The major fraction of ARH3 is found in the cytoplasm, and consistent with its inability to cleave the last, protein-bound ADP-ribose, its physiological function could be the hydrolysis of free PAR chains released during apoptotic cell death (119). More recently, Nudix hydrolases (Nucleoside diphosphate-linked moiety X hydrolases) emerged as new PAR processing enzymes, which can remove PAR and convert protein-bound ADP-ribose into ribose-5’-phosphate (R5P) marks, releasing phosphoribosyl-AMP (PRAMP) as byproduct (120). Nudix hydrolases might thus counteract PARP activity both directly by PAR degradation and indirectly by generating products that may interfere with PARP-dependent ADP-ribosylation and PAR chain elongation. The physiological relevance of the R5P modification and whether enzymes exist to revert it is currently not known.

From recent biochemical, structural and in vivo work it has become clear that the importance of processing and erasing PAR chains is at least equal to the importance of generating PAR, and that multiple enzymes, which combine PAR-recognition and PAR-degradation within their structures, are involved in limiting PAR production and ensuring its timely removal.

Targeting PARylation in human diseases

Inhibitors against the writers of PAR have been available for many years, and these compounds gained widespread attention when it was found that PARP inhibition specifically kills cancer cells with defects in the homologous recombination (HR) DNA repair pathway (121,122). The synthetic lethality conferred by PARP inhibition in HR-defective cancer cells has sparked a variety of pre-clinical and clinical trials, and in 2014 the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the PARP inhibitor Olaparib as a therapy against HR-compromised cancers. While the last decade has seen promising attempts to extend the spectrum of cancers that may respond to PARP inhibition beyond the origi-
PAR-seeded liquid demixing. PAR chains assemble hundreds of proteins, including many intrinsically disordered, low complexity domain-containing proteins, at sites of PAR formation, which collectively re-shape the local environment. This can lead to dynamic compartmentalization by liquid demixing, indicating that PAR can function as a general organizer of the soluble intracellular space.

Finally characterized BRCA1- and BRCA2-deficient cancer cells, also the first resistance mechanisms appeared. These include loss of PARP protein expression, up-regulation of the P-glycoprotein multidrug efflux pump, and restoration of HR function—either by re-activating mutations in the BRCA1/2 genes, or by loss of components of the competing non-homologous end-joining (NHEJ) pathway (123). Nevertheless, PARP inhibition continues to be a promising avenue in targeted cancer therapies based on the concept of synthetic lethality, and we may expect the spectrum of cancers that respond well to PARP inhibition to grow further, but also anticipate the appearance of additional resistance mechanisms that have to be considered when designing treatment regimens.

While the use of PARP inhibitors in cancer has advanced quickly during the last decade, the limited toxicity and good tolerability together with the broad spectrum of cellular processes regulated by PARylation make PARP inhibitors candidate drugs to treat also non-oncologic human diseases. Indeed, clinical potential has been described in disease settings related to cardiovascular dysfunction and inflammation (124–126). Moreover, efforts to further improve PARP inhibitors and make these compounds more specific toward single PARP family members have led to the notion that besides PARP1 and PARP2 also the tankyrases and potentially other ARTD family members might be promising targets in certain medical conditions including cancer (127–129). In addition to the inhibition of PAR writers, the development of potent, cell-permeable inhibitors of PAR erasers, in particular of PARG, has become an active field of research (130,131). However, efforts to further improve PARG inhibitors and make these compounds more specific toward single PARP family members have led to the notion that besides PARP1 and PARP2 also the tankyrases and potentially other ARTD family members might be promising targets in certain medical conditions including cancer (127–129).

In addition to the inhibition of PAR writers, the development of potent, cell-permeable inhibitors of PAR erasers, in particular of PARG, has become an active field of research (130,131). Given the delicate and highly dynamic balance between PAR formation and its degradation, PARG inhibitors might have therapeutic potential in settings in which PAR metabolism is deregulated, or in which impaired PAR degradation and the ensuing adverse effects on genome maintenance and survival would be clinically beneficial. Indeed, PARG is required to prevent detrimental accumulation of PAR upon prolonged replicative stress, and cells lacking PARG activity are hypersensitive to the replication inhibitor hydroxyurea (132), suggesting that PARG inhibition might synergize with chemotherapeutic approaches aimed at deliberately enhancing replication stress in cancer cells.

While targeting the writers and erasers of PARylation continues to be a promising avenue, little attention has been given to the possibility of targeting the readers of PARylation, despite the fact that many PAR functions are closely linked to non-covalent interactions between PAR-binding proteins and the anionic polymer. Although it might be challenging to design compounds that target the interface between PAR and PAR-binding proteins, in particular where structural information is still missing, promising examples exist in other areas of chromatin biology and provide a paradigm that PTM readers can be efficiently targeted, for instance in the case of epigenetic readers of the bromodomain and extra-terminal (BET) protein family (133). The disruption of interactions between PTMs and their readers could have significant, largely unexploited therapeutic potential. In particular with regard to PAR signaling, it might allow for the inhibition of sub-groups of PAR readers from binding to the polymer scaffold and thereby confer a higher level of specificity as compared to blocking PARP enzymes. Given that different PAR reader modules have evolved to perform specific cellular functions, targeting them individually or in sub-groups rather than abolishing PAR formation altogether may have a clear therapeutic potential. It may also help dissect different PAR functions and how they relate to different classes of PAR binders. For instance, specifically blocking genome caretakers from interacting with PAR at sites of DNA damage may compromise repair efficiency and result in synthetic lethal conditions, whereas blocking intrinsically disordered proteins from PAR-seeded self-assembly might decelerate their aggregation in certain pathological conditions. Mutations in these PAR-responsive proteins can enhance their aggregation propensity, thereby increasing the risk of turning dynamic, PAR-seeded phase transitions into irreversible aggregates that can compromise cell function (95,100). Likewise, deregulated PAR metabolism can result in pathologic PAR accumulation and cause fatal neurodegeneration (118,134,135). PARP activation and PAR formation have also been implicated in the onset of Alzheimer’s disease (136). Such neurodegenerative disease-associated changes
in writing, reading and erasing PARylation provide a rationale to test whether targeting PARylation by enzyme inhibitors or by yet to be developed competitive inhibitors of PAR-binding may have a clinical potential in neurodegenerative disorders.

CONCLUDING REMARKS

Due to the many facets of PAR biology and its relevance for human health and disease, significant attention has been attributed to the identification and characterization of writers, modifiers and erasers of this unusual PTM. Moreover, it was realized that reading the PAR signal by PAR-binding proteins constitutes a major aspect of PAR biology. Indeed, non-covalent interactions with PAR can drive the dynamic re-localization and site-specific assembly of hundreds of proteins, including many DNA repair factors, chromatin remodelers, histone variants, transcription factors and RNA processing factors. In light of the large number and functional diversity of proteins responsive to PAR signaling, unifying concepts may help us grasp this ever-increasing complexity. While certain PAR reader modules seem to possess highly specific PAR-binding folds, which recognize defined biochemical structures present in PAR, e.g. PBZ, WRE, and macrodomains, other reader modules seem to comprise sequence elements, which confer affinity to PAR, but which may also allow for interactions with nucleic acids or other PTMs. Examples include the PBM, FHA and BRCT domains, RRM, RG/RGG, SR and KR repeats, as well as OB-folds and PIN domains. Their structural and chemical properties enable them to undergo electrostatic, often multivalent interactions with PAR chains, which can cooperate to reach nanomolar affinities. In silico analyses of the human proteome as performed previously to identify PBMs (42) and RG/RGG motifs (87), combined with mass-spectrometric identification of PAR-associated complexes and their dynamics as well as in vitro affinity measurements will help to quantitatively define PAR-mediated protein assemblies under various cellular conditions. The tight control of PAR levels through context-dependent regulation of PARP enzymes as well as the rapid PAR turnover by erasers make this nucleic-acid like modification ideally suited to transiently outcompete other interactions in order to dynamically re-organize the soluble intracellular space. Consistent with PAR being able to outcompete protein-nucleic acid and protein-PTM interactions, non-consensus binding sites in highly expressed RNAs can compete efficiently with high-affinity consensus sequences in RNAs expressed at lower levels (137). Thus, rather than viewing interactions as either specific or nonspecific, it is necessary to realize that proteins possess affinity to a range of potential interaction partners and that dynamic changes in their relative availability determines which types of interactions manifest at any given time. Similar to highly expressed RNAs with low-affinity non-consensus binding sites, PAR could be regarded as an inducible nucleic acid-mimicking scaffold that lacks sequence information but is nevertheless able to transiently trap and sequester dozens to hundreds of proteins at sites of PARylation. This dynamic re-organization of multi-protein assemblies involves the phase separation of low complexity domain-containing proteins, and it is tempting to speculate that various aspects of cellular PAR functions are closely linked to PAR-seeded compartmentalization and the accompanying changes in the physicochemical environment. In this regard, PAR would share many features with RNAs as structural elements that control the biogenesis of nuclear bodies (138), closing the circle to the first description of PAR in 1963 as a polyadenylic acid (5).

ACKNOWLEDGEMENTS

We apologize to authors whose work could not be cited due to space limitations and are thankful to members of our institute for helpful discussions and comments on the manuscript. Research in the lab of M.A. is supported by the Swiss National Science Foundation (Grant PP00P3_150690/1) and by the University of Zurich Association Research Talent Development Fund.

FUNDING

Funding for open access charge: University of Zurich, Switzerland.

Conflict of interest statement. None declared.

REFERENCES

1. Schreiber, V., Dantzer, F., Ame, J.C. and de Murcia, G. (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 7, 517–528.
2. Burkle, A. (2005) Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J., 272, 4576–4589.
3. Hassa, P.O. and Hottiger, M.O. (2008) The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci., 13, 3046–3082.
4. Barkauskaite, E., Jankevicius, G., Ladurner, A.G., Ahel, I. and Timinszky, G. (2013) The recognition and removal of cellular poly(ADP-ribose) signals. FEBS J., 280, 3491–3507.
5. Chamoun, P., Weill, J.D. and Mandel, P. (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Bioch. Biophys. Res. Commun., 11, 39–43.
6. Kraus, W.L. (2015) PARPs and ADP-Ribosylation: 50 Years and Counting. Mol. Cell, 58, 902–910.
7. Bai, P. (2015) Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance. Mol. Cell, 58, 947–958.
8. Barkauskaite, E., Jankevicius, G. and Ahel, I. (2015) Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation. Mol. Cell, 58, 935–946.
9. Hottiger, M.O. (2015) Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics. Annu. Rev. Biochem., 84, 227–263.
10. Hottiger, M.O., Hassa, P.O., Luscher, B., Schuler, H. and Koch-Nolte, F. (2010) Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci., 35, 208–219.
11. Bock, F.J., Todorova, T.T. and Chang, P. (2015) RNA Regulation by Poly(ADP-Ribose) Polymerases. Mol. Cell, 58, 959–969.
12. Smeenk, G. and van Attikum, H. (2013) The chromatin response to DNA breaks: leaving a mark on genome integrity. Annu. Rev. Biochem., 82, 55–80.
13. Gibson, B.A. and Kraus, W.L. (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol., 13, 411–424.
14. Luo, X. and Kraus, W.L. (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev., 26, 417–432.
15. Menissier de Murcia, J., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Ame, J.C., Dierich, A.,...
35. Simbulan-Rosenthal, C.M., Rosenthal, D.S. and Smulson, M.E. (2011) Purification and characterization of poly(ADP-ribose)ylated DNA replication/repair complexes. *Methods Mol. Biol.*, 780, 165–190.

36. Matic, I., Abeli, I. and Hay, R.T. (2012) Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites. *Nat. Methods*, 9, 711–712.

37. Chapman, J.D., Gagne, J.P., Poirier, G.G. and Goodlett, D.R. (2013) Mapping PARP-1 auto-ADP-ribosylation sites by liquid chromatography-tandem mass spectrometry. *J. Proteome Res.*, 12, 1868–1880.

38. Gagne, J.P., Ethier, C., Defoy, D., Bourassa, S., Langelier, M.F., Riccio, A.A., Pascal, J.M., Moon, K.M., Foster, L.J., Ning, Z. et al. (2015) Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs. *DNA Repair*, 30, 68–79.

39. Daniels, C.M., Ong, S.E. and Leung, A.K. (2014) Phosphoproteomic Approach to Characterize Protein Mono- and Poly(ADP-ribosyl)ation Sites from Cells. *J. Proteome Res.*, 13, 3510–3522.

40. Daniels, C.M., Ong, S.E. and Leung, A.K. (2015) The Promise of Proteomics for the Study of ADP-Ribosylation. *Mol. Cell*, 58, 911–924.

41. Rosenthal, F. and Hottiger, M.O. (2014) Identification of ADP-ribosylated peptides and ADP-ribose acceptor sites. *Front. Biosci.*, 19, 1041–1056.

42. Gagne, J.P., Isabelle, M., Lin, K.S., Bourassa, S., Hendzel, M.J., Dawson, V.L., Dawson, T.M. and Poirier, G.G. (2008) Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. *Nucleic Acids Res.*, 36, 6959–6976.

43. Isabelle, M., Gagne, J.P., Gallouzi, I.E. and Poirier, G.G. (2012) Quantitative proteomics and dynamic imaging reveal that G3BP-mediated stress granule assembly is poly(ADP-ribose)-dependent following exposure to MNNG-induced DNA alkylation. *J. Cell Sci.*, 125, 4555–4566.

44. Jungmichel, S., Rosenthal, F., Altmeyer, M., Lukas, J., Hottiger, M.O. and Nielsen, M.L. (2013) Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. *Mol. Cell.*, 52, 272–285.

45. Zhang, Y., Wang, J., Ding, M. and Yu, Y. (2013) Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. *Nat. Methods*, 10, 981–984.

46. Psakhye, I. and Jentsch, S. (2012) Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. *Cell*, 151, 807–820.

47. Kretsch, J., Rouleau, M., Pic, E., Ethier, C., Dawson, T.M., Dawson, V.L., Masson, J.Y., Poirier, G.G. and Gagne, J.P. (2013) Reprogramming cellular events by poly(ADP-ribose)-binding proteins. *Mol. Aspects Med.*, 34, 1066–1087.

48. Gagne, J.P., Haince, J.F., Pic, E. and Poirier, G.G. (2011) Affinity-based assays for the identification and quantitative evaluation of noncovalent poly(ADP-ribose)-binding proteins. *Methods Mol. Biol.*, 780, 93–115.

49. Malanga, M. and Althaus, F.R. (2011) Noncovalent protein interaction with poly(ADP-ribose). *Methods Mol. Biol.*, 780, 67–82.

50. Kalisch, T., Ame, J.C., Dantzer, F. and Schreiber, V. (2012) New readers and interpretations of poly(ADP-ribose)ylation. *Trends Biochem. Sci.*, 37, 381–390.

51. Pleschke, J.M., Kleczkowski, H.E., Strohm, M. and Althaus, F.R. (2000) Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. *J. Biol. Chem.*, 275, 40974–40980.

52. Fahrer, J., Kranaster, R., Altmeyer, M., Marx, A. and Burkle, A. (2007) Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain length. *Nucleic Acids Res.*, 35, e143.

53. Fahrer, J., Popp, O., Malanga, M., Beneke, S., Markovitz, D.M., Ferrando-May, E., Burkle, A. and Kappes, F. (2010) High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length. *Biochemistry*, 49, 7119–7130.

54. Popp, O., Veith, S., Fahrer, J., Boehr, V.A., Burkle, A. and Manngerich, A. (2013) Site-specific noncovalent interaction of the biopolymer poly(ADP-ribose) with the Werner syndrome protein regulates protein functions. *ACS Chem. Biol.*, 8, 179–188.

55. Fischer, J.M., Popp, O., Gebhard, D., Veith, S., Fischbach, A., Beneke, S., Leitenstorfer, A., Bergemann, J., Scheffner, M., Ferrando-May, E. et al. (2014) Poly(ADP-ribose)-mediated interplay...
of XPA and PARP1 leads to reciprocal regulation of protein function. FEBS J. 281, 3625–3641.
56. Ahel, I., Ahel, D., Matsusaka, T., Clark, A.J., Pines, J., Boulton, S.J. and West,S.C. (2008) Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature, 451, 81–85.
57. Isogai, S., Kanno, S., Aizawa, M., Tochio, H., Ito, Y., Yasui, A. and Shirakawa, M. (2010) Solution structure of a zinc-finger domain that binds to poly-ADP-ribose. Genes Cells, 15, 101–110.
58. Oberoi, J., Richards, M.W., Crumpler, S., Brown, N., Blagg, J. and Bayliss, R. (2010) Structural basis of poly(ADP-ribose) recognition by the multizinc binding domain of Checkpoint with forkhead-associated and RING Domains (CHFR). J. Biol. Chem., 285, 39348–39358.
59. Eustermann, S., Brockmann, C., Mehrotra, P.V., Yang, J.C., Loakes, D., West, S.C., Ahel, I. and Neuhaus, D. (2010) Solution structures of the two PBZ domains from human APLF and their interaction with poly(ADP-ribose). Nat. Struct. Mol. Biol., 17, 241–243.
60. Li, G.Y., McCulloch, R.D., Fenton, A.L., Cheung, M., Meng, L., Ikura, M. and Koch, C.A. (2010) Structure and identification of ADP-ribose recognition motifs of APLF and role in the DNA damage response. Proc. Natl. Acad. Sci. U.S.A., 107, 9129–9134.
61. Rulten, S.L., Cortes-Ledesma, F., Guo, L., Iles, N.J. and Caldecott, K.W. (2008) APLF (C2orf13) is a novel component of poly(ADP-ribose) signaling in mammalian cells. Mol. Cell. Biol., 28, 4355–4368.
62. Min, W., Bruhn, C., Grigaravicius, P., Zhou, Z.W., Li, F., Kruger, A., Siddeek, B., Greulich, K.O., Popp, O., Meisezhc, C. et al. (2013) Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation. Nat. Commun., 4, 2993.
63. Ahel, I., Horreij, Z., Wiechens, N., Polo, S.E., Garcia-Wilson, E., Ahel, I., Flynn, H., Scheel, M., West, S.C., Jackson, S.P. et al. (2009) Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science, 325, 1240–1243.
64. Gottschalk, A.J., Timinszky, G., Kong, S.E., Jin, J., Cai, Y., Swanson, S.K., Washburn, M.P., Flores, L., Ladurner, A.G. and Conaway, J.W. et al. (2009) Poly(ADP-ribosylation) directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl. Acad. Sci. U.S.A., 106, 13770–13774.
65. Timinszky, G., Till, S., Hassa, P.O., Hothorn, M., Kustatscher, G., Nijmeijer, B., Colombelli, J., Altman, M., Steler, E.Z., Schellzck, K. et al. (2009) A macromdomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol., 16, 923–929.
66. Aguiar, R.C., Takeyama, K., Hee, C., Kreinbrink, K. and Shipp, M.A. (2005) B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J. Biol. Chem., 280, 33756–33765.
67. Wang, Z., Michaud, G.A., Cheng, Z., Zhang, Y., Hinds, T.R., Fan, E., Cong, F. and Wu, W. (2012) Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosylation)-dependent ubiquitination. Genes Dev., 26, 235–240.
68. Kang, H.C., Lee, Y.I., Shin, J.H., Andradi, S.A., Chi, Z., Gagne, J.P., Lee, Y., Ko, H.S., Lee, B.D., Poirier, G.G. et al. (2011) Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proc. Natl. Acad. Sci. U.S.A., 108, 14103–14108.
69. Perry, J.J., Tainer, J.A. and Boddy, M.N. (2008) A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem. Sci., 33, 201–208.
70. DaRosa, P.A., Wang, Z., Jiang, X., Pruneda, J.N., Cong, F., Klevit, R.E. and Xu, W. (2015) Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribose)ylation signal. Nature, 517, 223–226.
71. Khoronenkova, S.V. and Dianov, G.L. (2011) The emerging role of Mule and ARF in the regulation of base excision repair. FEBS Lett., 585, 2831–2835.
72. Gudjonsson, T., Altman, M., Savic, V., Toledo, L., Dimant, C., Groffe, M., Barrkova, J., Poulsen, M., Oka, Y., Bekker-Jensen, S. et al. (2012) TRIP12 and UBR5 suppress spreading of chromatin ubiquitination at damaged chromosomes. Cell, 150, 697–709.
73. Reinhartl, H.C. and Yaffe, M.B. (2013) Phospho-Ser-Thr-binding domains: navigating the cell cycle and DNA damage response. Nat. Rev. Mol. Cell. Biol., 14, 563–580.
93. Hong.Z., Jiang.I., Ma.J., Dai.S., Xu.T., Li.H. and Yasui,A. (2013) The role of hnRNP1 in DNA damage response is related to PARP1. PLoS One, 8, e60208.

94. Britton,S., Dernoncourt,E., Delteil,C., Froment,C., Schiltz.O., Salles,B., Fritt.P. and Calsou.P. (2014) DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin to R-loops removal. Nucleic Acids Res., 42, 9047–9062.

95. Altmeyer,M., Neelsen,K.J., Teloni,F., Pozdniyakova.I., Pellegrino,S., Grofte,M., Rask,M.B., Streicher,W., Jungmichel.S., Nielsen,M.L. (2015) Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nat. Commun., 6, 8088.

96. Kato,M., Han,T.W., Xie,S., Shi,K., Du,X., Wu,L.C., Mirzaei,H., Goldsmith,J.E., Longood,J., Pei,J. (2012) Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell, 149, 755–767.

97. Han,T.W., Kato,M., Xie,S., Wu,L.C., Mirzaei,H., Pei,J., Chen,M., Xie,Y., Allen,J., Xiao,G. et al. (2012) Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell, 149, 768–779.

98. Hyman,A.A. and Simons,K. (2012) Cell biology. Beyond oil and water–phase transitions in cells. Science, 337, 1047–1049.

99. Hyman,A.A., Weber,C.A. and Julicher,F. (2014) Liquid-liquid phase separation in biology. Annu. Rev. Cell Dev. Biol., 30, 39–58.

100. Patel,A., Lee,H.O., Jawerth,L., Maharana,S., Jahnel,M., Hein,M.Y., Stoynov,S., Mahmud,J., Saha,S., Franzmann,T.M. et al. (2015) A liquid-to-solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell, 162, 1066–1077.

101. Leung,A.K., Vyas,S., Rood,J.E., Bhutkar,A., Sharp,P.A. and Chang.P. (2011) Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol. Cell, 42, 489–499.

102. Kato,M., Han,T.W., Xie,S., Wu,L.C., Mirzaei,H., Pei,J., Chen,M., Xie,Y., Allen,J., Xiao,G. et al. (2012) Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell, 149, 755–767.

103. Slade,D., Dunstan,M.S., Barkauskaite,E., Weston,R., Laffe,P., Dixon,N., Ahel,M., Leys,D. and Ahel,I. (2011) The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature, 477, 616–620.

104. Kioussis,D. et al. (2015) A family of macrodomain proteins are new mono-ADP-ribosylhydrolases. Nat. Struct. Mol. Biol., 20, 502–507.

105. Ji,Y. and Tulin,A.V. (2013) Post-transcriptional regulation by PARPs. Nat. Rev. Mol. Cell. Biol., 14, 380–393.

106. Kwon,I., Kato,M., Xiang,S., Wu,L., Theodoropoulos,P., Kraus,W.L. and Hottiger,M.O. (2013) PARP-1 and gene regulation. Nat. Commun., 3, 878.

107. Lambrecht,M.J., Brichacek,M., Barkauskaite,E., Ariza,A., Ahel,I. and Hergenreter,P.J. (2015) Synthesis of dimeric ADP-ribose and its structure with human poly(ADP-ribose) glycohydrolase. J. Am. Chem. Soc., 137, 3558–3564.

108. Jankevicius,H., Hassler,M., Goila,B., Rybin,V., Zacharias,M., Timinszky,G. and Ladurner,A.G. (2013) A family of macrodomain proteins reverses cellular mono-ADP-riboseylation. Nat. Struct. Mol. Biol., 20, 508–514.

109. Lord,C.J. and Ashworth,A. (2012) Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Mol. Aspects Med., 33, 1109–1123.

110. Curtin,N.J. and Szabo,C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med., 34, 1217–1256.

111. Bryant,H.E., Schultz,N., Thomas,H.D., Parker,K.M., Flower,D., Lopez,E., Kyle,S., Meuth,M., Curtin,N.J. and Helleday,T. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917.

112. Curtin,N.J. and Szabo,C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med., 34, 1217–1256.

113. Lord,C.J. and Ashworth,A. (2013) Mechanisms of resistance to therapies targeting PARP1-mutant cancers. Nat. Med., 19, 1381–1388.

114. Dunstan,M.S., Barkauskaite,E., Laffe,P., Knezevic,C.E., Brassington,A., Ahel,M., Hergenrether,P.J., Leys,D. and Ahel,I. (2012) Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase. Nat. Struct. Mol. Biol., 19, 1289–1295.

115. Back, M.T., De Boer, M., and Hottiger, M.O. (2012) Val 718 in PARP1 mediates sensitivity to Nec-1 and Nec-17. Biochem. J., 443, 647–653.

116. Lord,C.J. and Ashworth,A. (2012) Tankyrse-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov., 11, 923–936.

117. Hyman,A.A., Weber,C.A. and Julicher,F. (2014) Liquid-liquid phase separation in biology. Annu. Rev. Cell Dev. Biol., 30, 39–58.

118. Bryant,H.E., Schultz,N., Thomas,H.D., Parker,K.M., Flower,D., Lopez,E., Kyle,S., Meuth,M., Curtin,N.J. and Helleday,T. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917.

119. Lord,C.J. and Ashworth,A. (2013) Mechanisms of resistance to therapies targeting PARP1-mutant cancers. Nat. Med., 19, 1381–1388.

120. Fang,F.Y., de Bono,J.S., Rubin,M.A. and Knudsen,K.E. (2015) Chromatin to Clinic: The Molecular Rationale for PARP Inhibitor Function. Mol. Cell, 58, 925–934.

121. Curtin,N.J. and Szabo,C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med., 34, 1217–1256.

122. Hottiger,M.O. (2015) Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface? Expert Opin. Ther. Targets, 19, 1149–1152.

123. Lord,C.J. and Ashworth,A. (2012) Tankyrse-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov., 11, 923–936.

124. Hyman,A.A., Weber,C.A. and Julicher,F. (2014) Liquid-liquid phase separation in biology. Annu. Rev. Cell Dev. Biol., 30, 39–58.

125. Curtin,N.J. and Szabo,C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med., 34, 1217–1256.

126. Lord,C.J. and Ashworth,A. (2012) Tankyrse-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov., 11, 923–936.

127. Hyman,A.A., Weber,C.A. and Julicher,F. (2014) Liquid-liquid phase separation in biology. Annu. Rev. Cell Dev. Biol., 30, 39–58.

128. Lord,C.J. and Ashworth,A. (2013) Mechanisms of resistance to therapies targeting PARP1-mutant cancers. Nat. Med., 19, 1381–1388.

129. Fang,F.Y., de Bono,J.S., Rubin,M.A. and Knudsen,K.E. (2015) Chromatin to Clinic: The Molecular Rationale for PARP Inhibitor Function. Mol. Cell, 58, 925–934.

130. Curtin,N.J. and Szabo,C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med., 34, 1217–1256.
(2010) Selective inhibition of BET bromodomains. *Nature*, 468, 1067–1073.

134. Cozzi, A., Cipriani, G., Fossati, S., Faraco, G., Formentini, L., Min, W., Cortes, U., Wang, Z. Q., Moroni, F. and Chiarugi, A. (2006) Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. *J. Cereb. Blood Flow Metab.*, 26, 684–695.

135. Hanai, S., Kanai, M., Ohashi, S., Okamoto, K., Yamada, M., Takahashi, H. and Miwa, M. (2004) Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. *Proc. Natl. Acad. Sci. U.S.A.*, 101, 82–86.

136. Abeti, R. and Duchen, M. R. (2012) Activation of PARP by oxidative stress induced by beta-amyloid: implications for Alzheimer’s disease. *Neurochem. Res.*, 37, 2589–2596.

137. Jankowsky, E. and Harris, M. E. (2015) Specificity and nonspecificity in RNA-protein interactions. *Nat. Rev. Mol. Cell Biol.*, 16, 533–544.

138. Dundr, M. and Misteli, T. (2010) Biogenesis of nuclear bodies. *Cold Spring Harb. Perspect. Biol.*, 2, a000711.